Barak Singer
Co-Founder & CEO @ Or Capital Healthcare Partners
Barak Singer is a seed investor at Or Capital Healthcare Partners focused on Medical and Health Care. Co-Founded Or Capital Healthcare Partners in 201415 years of experience in management, business development, investment banking and venture capitalActed as Managing Director, Co-Head of Investment Banking, Head of Healthcare, at Tamir Fishman & Co. representing the Royal Bank of Canada's (NYSE:RY) investment banking arm RBCCapital Markets in IsraelHeld key management positions:Vice President of Business Development at Can-Fite BioPharma (NYSE: CANF) and CEO of its subsidiary OphthaliXVice President of Business Development at Xenia Venture CapitalEstablished and served on the board of Xenia’s portfolio company Xenolith MedicalB.A in Business, LLB in Law – The Interdisciplinary Center
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Barak Singer invests in
Stages Barak Singer invests in
Countries Barak Singer invests in
Investment Focus
Industry
- Medical 1 (33%)
- Health Care 1 (33%)
- Medical Device 1 (33%)
Stage
- Seed 1 (33%)
- Funding Round 1 (33%)
- Debt Financing 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SetBone Medical
|
SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis. | $1.6M / Debt Financing / Jan 26, 2022 | |
Vessi Medical
|
Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | Aug 31, 2020 | |
|
Vessi Medical
|
Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | $1.7M / Seed / Aug 31, 2020 |
Co-Investors
About Or Capital Healthcare Partners
Or Capital Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Barak Singer
Co-Founder & CEO
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Barak Singer invest in?
Barak Singer invests primarily in Medical, Health Care and Medical Device startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Barak Singer last invest?
The most recent investment recorded for Barak Singer closed in Jan 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
